Chiromics, a drug discovery company based in Princeton, N.J., has formed a strategic research alliance with global biopharmaceutical company Bristol-Myers Squibb.

The research alliance includes grants of non-exclusive license for use of Chiromics' chemical compound library, exclusive license to a proprietary chemical compound collection and a screening collaboration to discover and optimize novel classes of small molecules against multiple therapeutic targets.

Chiromics' compound collections are assembled using Chiromics' core chemical technology referred to as "cascade catalysis." This technology was invented in the MacMillan Laboratories at Princeton University. Cascade catalysis allows for the creation of "accessible complexity," a diverse collection of molecules that is more complex than and differentiated from currently existing small molecule collections, while retaining drug-like properties, the ability to develop structure-activity relationships and ease of re-synthesis.

The synergistic combination of Chiromics' chemical compound collection of accessible complexity, and Chalis, Chiromics' exclusive hit recognition algorithm for affinity selection, enables the identification of new lead molecules that is complementary to conventional high throughput screening processes.

"We are delighted that Bristol-Myers Squibb has chosen Chiromics as a drug discovery partner based on their proven commitment to innovation and reputation as a strong collaborator with biotech companies,” said David MacMillan, Ph.D., founder of Chiromics. “This collaboration further authenticates that Chiromics' chemical technology and discovery platform is a unique gateway to a new set of small molecules for drug discovery."